#MSParis2017

November 20, 2017November 28, 2017

Nearly 1 Million Americans Have Multiple Sclerosis, NMSS Prevalence Study Finds

News

An estimated 947,000 people in the U.S. have multiple sclerosis — more than double the long-accepted figure of 400,000 — according to a newly completed ... Read more

November 3, 2017November 3, 2017

#MSParis2017 – Merck Announces Winners of 1 Million Euro Grant for Innovative Multiple Sclerosis Research

News

Research teams from Canada, Portugal and the United States, each with projects focused on predicting and defining characteristics of multiple sclerosis (MS) , will share this year’s 1 ... Read more

November 2, 2017November 2, 2017

#MSParis2017 – Almost Half of MS Patients Fail to Report Relapses, Two Surveys Show

News

Nearly half of multiple sclerosis patients do not always report their relapses to healthcare providers, two surveys indicate. Mallinckrodt sponsored the surveys to better understand patients’ experience with ... Read more

November 1, 2017November 13, 2017

#MSParis2017 – EVOLVE-MS-1 Interim Trial Data Shows Alkermes Therapy Safe for Treating Relapsing MS

News

Preliminary data from the Phase 3 EVOLVE-MS-1 trial shows that ALKS 8700 — an investigative therapy developed by Alkermes to treat relapsing forms of multiple sclerosis — has a good ... Read more

November 1, 2017November 1, 2017

#MSParis2017 – MS Places Heavy Burdens on Women, Study in 8 European Countries Shows

News

Multiple sclerosis (MS) can have severe implications on the lives of European women with the disease, finds a new report, affecting their education, their careers and ... Read more

October 31, 2017October 31, 2017

#MSParis2017 – Advances in Progressive and Pediatric MS Top ECTRIMS Highlights, NMSS Says

News

A giant leap in research and interest in progressive multiple sclerosis — from a few people pushing for such work to 2,000 listening to updates on ... Read more

October 31, 2017October 31, 2017

#MSParis2017 – Ocrevus Trial Data May Lead to Key Biomarkers of Chronic Inflammation, Genentech Says

News

Potential new ways of capturing disease progression in multiple sclerosis (MS) patients — including those with chronic as opposed to active inflammation — are coming to ... Read more

October 31, 2017October 31, 2017

#MSParis2017 – T-cell vs. B-cell Debate More Meeting of Minds Than ‘Rumble in the Jungle’

News

News commentary One particular session on Day 2 of the four-day 7th Joint ECTRIMS-ACTRIMS Meeting — which drew 10,000 researchers, doctors, industry representatives, and patient advocates ... Read more

October 31, 2017October 31, 2017

#MSParis2017 – Scant Difference Seen in Inflammatory Response to Ocrevus or Rituxan in Small Study

News

Both Ocrevus (ocrelizumab) and Rituxan (rituximab) trigger a similar release of inflammatory mediators after a first infusion, with little difference seen in infusion reactions among a ... Read more

October 30, 2017October 31, 2017

#MSParis2017 – Aubagio Can Help Slow Progression to an MS Diagnosis, Researcher Says

News

Aubagio (teriflunomide) can help to delay first clinical signs of multiple sclerosis (MS) from progressing to a definite diagnosis in a person, and treatment should likely begin ... Read more

October 30, 2017October 30, 2017

#MSParis2017 – RADIANCE Trial Data Shows Ozanimod’s Potential Over Interferon Beta-1a for Relapsing MS

News

Celgene‘s investigative drug ozanimod has been shown to be more efficient than an intramuscular injection of interferon beta-1a (marketed as Avonex by Biogen) in reducing relapses and disease ... Read more

October 30, 2017November 4, 2017

#MSParis2017 – GNbAC1 Promotes Restoration of Protective Myelin Coating, Phase 2b Trial Shows

News

GeNeuro‘s humanized antibody GNbAC1 promotes the rejuvenation of the myelin coating that protects nerve cells in patients with relapsing-remitting multiple sclerosis, or RRMS, a Phase 2 clinical trial shows. ... Read more

October 30, 2017October 30, 2017

#MSParis2017 – Promising Work in Pediatric and Secondary Progressive Patients Is Focus, Novartis Says in Interview

News

Gilenya (fingolimod) lowered relapse rates in children and adolescents with relapsing multiple sclerosis at a “magnitude” — almost 82 percent — never before seen in a ... Read more

October 30, 2017October 30, 2017

MS News That Caught My Eye Last Week: #MSParis, Biotin, Tysabri, Lemtrada, Propionic Acid Reports

Columns, The MS Wire - A Column by Ed Tobias

There’s been a lot of interest in the treatments (including natural treatments) for progressive MS that were presented at the ECTRIMS-ACTRIMS conference in Paris last week. ... Read more

October 30, 2017October 31, 2017

#MSParis2017 – Ibudilast Slows Loss of Brain Tissue in MS Patients, Phase 2 Trial Shows

News

The Japanese company MediciNova‘s anti-inflammatory agent ibudilast slows multiple sclerosis patients’ brain shrinkage and their loss of the protective myelin coating around nerve cells, a Phase 2 clinical ... Read more

October 30, 2017October 30, 2017

#MSParis2017 – Gilenya Seen to Reduce Relapses in Children with Active MS

News

Gilenya (fingolimod) was seen to significantly reduce relapses in children and teenagers with multiple sclerosis (MS), according to data from a Phase 3 study — the ... Read more

October 30, 2017November 3, 2017

#MSParis2017 – Trial to See if Disease-modifying Therapies Not Necessary in Older MS Patients

News

A clinical study now enrolling people with progressive or relapsing multiple sclerosis will examine the feasibility of older patients stopping use of disease-modifying therapies if they ... Read more

October 30, 2017November 3, 2017

#MSParis2017 – Aerobic Exercise Seen to Quickly Strengthen Brain Connections in Patients

News

Aerobic exercise strengthens brain connections in people with relapsing-remitting multiple sclerosis, Jan-Patrick Stellmann, with University Medical Center Hamburg-Eppendorf in Germany, reported at the 7th Joint ECTRIMS-ACTRIMS Meeting ... Read more

October 27, 2017October 30, 2017

#MSParis2017 – Lemtrada Shows Good Safety and Lasting Efficacy Over 7 Years, Doctor Says in Interview

News

Lemtrada (alemtuzumab) remains a “game-changer” of a treatment for relapsing multiple sclerosis (MS), with benefits continuing and no new side effects seen in a study of ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Early High-Efficacy Treatment Reduces Disability Accumulation in Young MS Patients

News

While early use of high-efficacy treatments lowers relapse rates among patients with relapsing-remitting multiple sclerosis (MS) compared to lower-efficacy ones, starting these therapies earlier may only ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Phase 3 Trial Data Show Ozanimod Safe, Effective in MS Patients

News

Ozanimod (RPC1063) was seen to lower relapse rates and reduce brain and spinal cord lesions among patients with relapsing multiple sclerosis (MS) participating in a Phase ... Read more

October 27, 2017October 30, 2017

#MSParis2017 – Potential Progressive MS Treatment on Move in US and Europe, MedDay CEO Says

News

This is a special edition of Multiple Sclerosis News Today’s daily Alexa Flash Briefing, covering the latest news from the 7th Joint ECTRIMS-ACTRIMS Meeting currently underway ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Quitting Smoking, Boosting Vitamin D Reduces MS Healthcare Costs, Improves Outcomes

News

People with multiple sclerosis (MS) who quit smoking have better health outcomes than those who continue. Therefore, MS-related costs can be reduced by encouraging smokers to quit. Similar ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Beta-Interferon Therapies May Increase Survival of MS Patients, Study Suggests

News

Long-term exposure of at least three years of beta-interferon therapies such as Rebif or Avonex may increase the survival of multiple sclerosis (MS) patients, a population-based study ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Multiple Sclerosis Can Stay Mild for Decades, 30-year British Study Shows

News

After the first round of symptoms, multiple sclerosis can stay mild without causing major problems for decades, a 30-year British study indicates. Karen K. Chung of the University College ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – MS Therapy Aubagio Does Not Appear to Cause Birth Defects, Study Reports

News

Sanofi Genzyme’s multiple sclerosis therapy Aubagio (teriflunomide) does not appear to cause birth defects in humans as it does in laboratory animals, researchers concluded after studying more than ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Immune Response to Epstein-Barr and Low Vitamin D Levels Separately Increase MS Risk

News

A strong immune reaction to an Epstein-Barr virus infection and low levels of vitamin D appear to increase the risk of multiple sclerosis (MS) independent of ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Researchers Suggest Best Time to Stop Tysabri During Pregnancy

News

Babies born to women who are treated with Tysabri (natalizumab) during pregnancy are more likely to develop abnormal blood cell counts if the treatment continues beyond ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Anti-inflammatory Therapies May Be More Beneficial for Younger SPMS Patients, Study Suggests

News

Older patients with secondary progressive multiple sclerosis (SPMS) have reduced risk of experiencing disease relapse, according to a study presented at the 7th Joint ECTRIMS-ACTRIMS Meeting, being ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Ocrevus Improves Relapsing MS Patients’ Vision Better Than Interferon, Trials Show

News

Genentech’s Ocrevus (ocrelizumab) improved the vision of people with relapsing multiple sclerosis better than the widely used therapy interferon beta-1a, according to clinical trial findings presented at the ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Real-world Data Leading Way to Personalized Treatment, Biogen Says in Interview

News

Personalized medicine is the future of multiple sclerosis treatment, and research now taking place to collect and analyze data and pinpoint biomarkers will help make possible ... Read more

October 27, 2017October 27, 2017

#MSParis2017 – Inhibiting Protein in Brain Cells Can Rejuvenate Protective Nerve Cell Coating, Study Shows

News

Inhibiting a protein found at high levels in immune cells located in the brain can rejuvenate myelin, the protective coating around nerve cells, according to a ... Read more

October 26, 2017October 27, 2017

#MSParis2017 – Researchers Disagree on Feasibility of Using Disease-modifying Therapies in RIS Patients

News

Radiologically isolated syndrome (RIS) is a rare and relatively recent condition in which people have multiple sclerosis (MS)-like brain and spinal cord lesions without showing disease ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – Mavenclad Is ‘Smart’ Therapy for Active Relapsing MS, Researcher Says

News

Mavenclad (cladribine tablets), an oral therapy by Merck that’s approved to treat people with active relapsing multiple sclerosis in much of Europe, is a “smart therapy” that is showing ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – Tysabri Did Improve Walking and Hand Function in Failed SPMS Trial, Researchers Say

News

While Tysabri (natalizumab) failed to slow worsening disability in people with secondary progressive multiple sclerosis (SPMS) in a Phase 3 trial, researchers now suggest that the ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – MedDay’s High-Dose Biotin, MD1003, Improves Disability in Progressive MS Patients

News

MD1003, a high-dose biotin developed by MedDay, slowed or prevented further disease progression among progressive multiple sclerosis (MS) patients in a Phase 3 clinical trial, researchers announced ... Read more

October 26, 2017October 27, 2017

#MSParis2017 – Siponimod Leads to Dramatic Drop in MS Lesions, Phase 3 Trial Shows

News

Novartis’ Siponimod led to a dramatic drop in the number of inflammation patches in the brains and spinal cords of secondary progressive multiple sclerosis patients, according to a ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – Lemtrada and Tysabri More Efficient Than Older Injectables in Preventing SPMS Onset, Study Finds

News

Sanofi Genzyme‘s Lemtrada (alemtuzumab) and Biogen‘s Tysabri (natalizumab) are more effective in preventing conversion to secondary progressive multiple sclerosis (SPMS) compared to older injectable drugs, researchers ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – Intellectual Enrichment Strategies May Improve Cognitive, Socio-Professional Outcomes of Pediatric-Onset MS

News

Using strategies to promote intellectual enrichment among patients with pediatric-onset multiple sclerosis could be essential to achieving better cognitive, social, and professional performances during adult life, ... Read more

October 26, 2017October 26, 2017

#MSParis2017 – Study Links Depression to Increased Disability in Women with MS

News

A University of British Columbia study found a link between depression and increased disability in women with multiple sclerosis. Dr. Kyla McKay said the study of more than 1,200 patients ... Read more